An armamentarium of wart treatments

Clinical Medicine and Research

Volumn 4, Issue 4, 2006, Pages 273-293

  Lipke, Michelle M ^a  

^a MARSHFIELD CLINIC   (United States)

Author keywords

Bleomycin; Cantharidin; Cryotherapy; Diphencyprone; Human papilloma virus; Imiquimod; Laser; Vaccine; Virucidal; Wart

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ABACAVIR; ALPHA INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; BENZALKONIUM; BLEOMYCIN; CANDIDA ANTIGEN; CANTHARIDIN; CIDOFOVIR; CIMETIDINE; DIDANOSINE; DIPHENCYPRONE; EFAVIRENZ; FLUOROURACIL; FORMALDEHYDE; FORMIC ACID; GARLIC EXTRACT; GLUTARALDEHYDE; IMIQUIMOD; LEVAMISOLE; PLACEBO; PODOPHYLLIN; PODOPHYLLOTOXIN; RETINOID; SALICYLIC ACID; STAVUDINE; UNINDEXED DRUG; VIDARABINE; ZINC SULFATE;

ALTERNATIVE MEDICINE; BURN; CARBON DIOXIDE LASER; CAUTERIZATION; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CRYOTHERAPY; DRUG HALF LIFE; ERBIUM YAG LASER; ERYTHEMA; EVIDENCE BASED PRACTICE; GENITAL TRACT INFECTION; HISTOPATHOLOGY; HUMAN; HYPERPIGMENTATION; HYPNOSIS; INJECTION PAIN; LYMPHANGITIS; MICROWAVE THERAPY; MONOTHERAPY; NEODYMIUM LASER; PAIN; PHOTODYNAMIC THERAPY; PULSED DYE LASER; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SWELLING; UTERINE CERVIX CANCER; VERRUCA VULGARIS; WART VIRUS;

EID: 33846612844     PISSN: 15394182     EISSN: None     Source Type: Journal    
DOI: 10.3121/cmr.4.4.273     Document Type: Review

References (301)

1. Leman JA, Benton EC. Verrucas. Guidelines for management. Am J Clin Dermatol 2000;1:143-149.
2. Ciconte A, Campbell J, Tabrizi S, Garland S, Marks R. Warts are not merely blemishes on the skin: A study on the morbidity associated with having viral cutaneous warts. Australas J Dermatol 2003;44:169-173.
3. Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003;(31):3-13.
4. Gunter J. Genital and perianal warts: new treatment opportunities for human papillomavirus infection. Am J Obstet Gynecol 2003;189:S3-S11.
5. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005;32(Suppl 1):S16-S24.
6. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-265.
7. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
8. Frimberger D, Schneede P, Hungerhuber E, Sroka R, Zaak D, Siebels M, Hofstetter A. Autofluorescence and 5-aminolevulinic acid induced fluorescence diagnosis of penile carcinoma - new techniques to monitor Nd:YAG laser therapy. Urol Res 2002;30:295-300.
9. Bragg JW, Ratner D. Human papillomavirus type 2 in a squamous cell carcinoma of the finger. Dermatol Surg 2003;29:766-768.
10. Herrero R. Chapter 7: Human papillomavirus and cancer of the upper aerodigestive tract. J Natl Cancer Inst Monogr 2003;(31):47-51.
11. Pfister H. Chapter 8: Human papillomavirus and skin cancer. J Natl Cancer Inst Monogr 2003;(31):52-56.
12. Gillison ML, Shah KV. Chapter 9: Role of mucosal human papillomavirus in nongenital cancers. J Natl Cancer Inst Monogr 2003;(31):57-65.
13. Chen YC, Chen JH, Richard K, Chen PY, Christiani DC. Lung adenocarcinoma and human papillomavirus infection. Cancer 2004;101:1428-1436.
14. Hama N, Ohtsuka T, Yamazaki S. Squamous cell carcinoma of the penis in a man with a human papilloma virus 31 infection. J Dermatol 2005;32:581-584.
15. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005;337:76-84.
16. Akgul B, Pfefferle R, Marcuzzi GP, Zigrino P, Krieg T, Pfister H, Mauch C. Expression of matrix metalloproteinase (MMP)-2, MMP-9, MMP-13, and MT1-MMP in skin tumors of human papillomavirus type 8 transgenic mice. Exp Dermatol 2006;15:35-42.
17. Katori H, Nozawa A, Tsukuda M. Increased expression of matrix metalloproteinase-2 and 9 and human papilloma virus infection are associated with malignant transformation of sinonasal inverted papilloma. J Surg Oncol 2006;93:80-85.
18. Gibbs S, Harvey I, Sterling J, Stark R. Local treatments for cutaneous warts: systematic review. BMJ 2002;325:461.
19. Gibbs S, Harvey I, Sterling JC, Stark R. Local treatments for cutaneous warts. Cochrane Database Syst Rev 2003;(3):CD001781.
20. Sterling JC, Handfield-Jones S, Hudson PM; British Association of Dermatologists. Guidelines for the management of cutaneous warts. Br J Dermatol 2001;144:4-11.
21. Chow KM. Physicians need more evidence on treatments of warts. Am Fam Physician 2003;68:1714.
22. Stulberg DL, Hutchinson AG. Molluscum contagiosum and warts. Am Fam Physician 2003;67:1233-1240.
23. Stulberg DL, Hutchinson AG. Physicians need more evidence on treatments of warts: in reply. Am Fam Physician. 2003;68:1714, 1716. Available at: http://www.aafp.org/afp/20031101/letters.html. Accessed May 10, 2006.
24. Fox PA, Tung MY. Human papillomavirus: burden of illness and treatment cost considerations. Am J Clin Dermatol 2005;6:365-381.
25. Drake LA, Ceilley RI, Cornelison RL, Dobes WL, Dorner W, Goltz RW, Lewis CW, Salasche SJ, Turner ML, Lowery BJ, Shama SK, Androphy EJ, Galen WK, Heaton CL, Lynch PJ, Chanco Turner ML. Guidelines of care for warts: human papillomavirus. Committee on Guidelines of Care. J Am Acad Dermatol 1995;32:98-103.
26. Micali G, Dall'Oglio F, Nasca MR, Tedeschi A. Management of cutaneous warts: an evidence-based approach. Am J Clin Dermatol 2004;5:311-317.
27. Agency for Healthcare Research and Quality. Guideline for the management of cutaneous warts. National Guideline Clearinghouse. Available at: http://www.guideline.gov/summary/summary.aspx?doc_id=6 628&nbr= 004172&string=Cutaneous+AND+warts. Accessed May 10, 2006.
28. Agency for Healthcare Research and Quality. 2002 national guideline for the management of anogenital warts. National Guideline Clearinghouse. Available at: http://www.guideline.gov/summary/summary.aspx?doc_id=3 046. Accessed December 13, 2005.
29. Bandolier. Genital wart treatments. Available at: http://www.jr2.ox.ac. uk/bandolier/band82/b82-3.html. Accessed December 6, 2005.
30. Rivera A, Tyring SK. Therapy of cutaneous human Papillomavirus infections. Dermatol Ther 2004;17:441-448.
31. Kirnbauer R, Lenz P, Okun MM. Human Papillomavirus. In: Bolognia J, Jorizzo J, Rapini R, eds. Dermatology. 1st ed. London: Mosby; 2003:1217-1233.
32. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003;(31):14-19.
33. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004;324:17-27.
34. Brotzman GL. Evaluating the impact of HPV-related diseases: Cervical cancer and genital warts. J Fam Pract 2005;54(7 Suppl):S3-9.
35. Gravitt PE, Jamshidi R. Diagnosis and management of oncogenic cervical human papillomavirus infection. Infect Dis Clin North Am 2005;19:439-458.
36. Villa LL. Prophylactic HPV vaccines: Reducing the burden of HPV-related diseases. Vaccine 2005; [Epub ahead of print].
37. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-278.
38. Mendez F, Munoz N, Posso H, Molano M, Moreno V, van den Brule AJ, Ronderos M, Meijer C, Munoz A; Instituto Nacional de Cancerologia Human Papillomavirus Study Group. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J Infect Dis 2005;192:1158-1165.
39. Vandepapeliere P, Barrasso R, Meijer CJ, Walboomers JM, Wettendorff M, Stanberry LR, Lacey CJ. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 2005;192:2099-2107.
40. Elbasha EH, Galvani AP. Vaccination against multiple HPV types. Math Biosci 2005;197:88-117.
41. Goncalves MA, Donadi EA. Immune cellular response to HPV: current concepts. Braz J Infect Dis 2004;8:1-9.
42. Ho GY, Studentsov YY, Bierman R, Burk RD. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004;13:110-116.
43. Rintala MA, Grenman SE, Jarvenkyla ME, Syrjanen KJ, Syrjanen SM. High-risk types of human papillomavirus (HPV) DNA in oral and genital mucosa of infants during their first 3 years of life: experience from the Finnish HPV Family Study. Clin Infect Dis 2005;41:1728-1733.
44. Clifton MM, Johnson SM, Roberson PK, Kincannon J, Horn TD. Immunotherapy for recalcitrant warts in children using intralesional mumps or Candida antigens. Pediatr Dermatol 2003;20:268-271.
45. Bellew SG, Quartarolo N, Janniger CK. Childhood warts: an update. Cutis 2004;73:379-384.
46. Smolinski KN, Yan AC. How and when to treat molluscum contagiosum and warts in children. Pediatr Ann 2005;34:211-221.
47. Massing AM, Epstein WL. Natural history of warts. A two-year study. Arch Dermatol 1963;87:306-310.
48. Allen AL, Siegfried EC. The natural history of condyloma in children. J Am Acad Dermatol 1998;39:951-955.
49. Yesudian PD, Parslew RA. Treatment of recalcitrant plantar warts with imiquimod. J Dermatolog Treat 2002;13:31-33.
50. Tosti A, Piraccini BM. Nail disorders. In: Bolognia, J, Jorizzo J, Rapini R, eds. Dermatology. 1st ed. London: Mosby; 2003:1061-1078.
51. Kimberlin DW. Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis. Antiviral Res 2004;63:141-151.
52. Madinier I, Monteil RA. Human papillomaviruses in oral epithelial lesions. Comparative study between histopathology and immunohistochemistry in routine diagnosis. J Biol Buccale 1987;15:105-110.
53. Terai M, Takagi M, Matsukura T, Sata T. Oral wart associated with human papillomavirus type 2. J Oral Pathol Med 1999;28:137-140.
54. Lilly EA, Cameron JE, Shetty KV, Leigh JE, Hager S, McNulty KM, Cheeks C, Hagensee ME, Fidel PL Jr. Lack of evidence for local immune activity in oral hairy leukoplakia and oral wart lesions. Oral Microbiol Immunol 2005;20:154-162.
55. van Brederode RL, Engel ED. Combined cryotherapy/70% salicylic acid treatment for plantar verrucae. J Foot Ankle Surg 2001;40:36-41.
56. Kuykendall-Ivy TD, Johnson SM. Evidence-based review of management of nongenital cutaneous warts. Cutis 2003;71:213-222.
57. Lowry DR, Androphy EJ. Warts. In: Freedberg IM, Eisen AZ, Klaus W, Austen KF, Goldsmith LA, Katz SI, eds. Fitzpatrick's dermatology in general medicine, vol. 2. 6th ed. New York: McGraw-Hill Inc;2003. 2119-2131.
58. Bolton RA. Nongenital warts: classification and treatment options. Am Fam Physician 1991;43:2049-2056.
59. Sanclemente G, Gill DK. Human papillomavirus molecular biology and pathogenesis. J Eur Acad Dermatol Venereol 2002;16:231-240.
60. Johnson RF, Barber TX. Hypnosis, suggestions, and warts: an experimental investigation implicating the importance of "believed-in efficacy". Am J Clin Hypn 1978;20:165-174.
61. Straatmeyer AJ, Rhodes NR. Condylomata acuminata: results of treatment using hypnosis. J Am Acad Dermatol 1983;9:434-436.
62. Spanos NP, Williams V, Gwynn MI. Effects of hypnotic, placebo, and salicylic acid treatments on wart regression. Psychosom Med 1990;52:109-114.
63. Ewin DM. Hypnotherapy for warts (verruca vulgaris): 41 consecutive cases with 33 cures. Am J Clin Hypn 1992;35:1-10.
64. Meineke V, Reichrath J, Reinhold U, Tilgen W. Verrucae vulgares in children: successful simulated X-ray treatment (a suggestion-based therapy). Dermatology 2002;204:287-289.
65. Ferreira JB, Duncan BR. Biofeedback-assisted hypnotherapy for warts in an adult with developmental disabilities. Altern Ther Health Med 2002;8:144,140-142.
66. Goldstein RH. Successful repeated hypnotic treatment of warts in the same individual: a case report. Am J Clin Hypn 2005;47:259-264.
67. Bakke AC, Purtzer MZ, Newton P. The effect of hypnotic-guided imagery on psychological well-being and immune function in patients with prior breast cancer. J Psychosom Res 2002;53:1131-1137.
68. Gruzelier JH. A review of the impact of hypnosis, relaxation, guided imagery and individual differences on aspects of immunity and health. Stress 2002;5:147-163.
69. Wood GJ, Bughi S, Morrison J, Tanavoli S, Tanavoli S, Zadeh HH. Hypnosis, differential expression of cytokines by T-cell subsets, and the hypothalamo-pituitary-adrenal axis. Am J Clin Hypn 2003;45:179-196.
70. Weber ND, Andersen DO, North JA, Murray BK, Lawson LD, Hughes BG. In vitro virucidal effects of Allium sativum (garlic) extract and compounds. Planta Med 1992;58:417-423.
71. Seki T, Tsuji K, Hayato Y, Moritomo T, Ariga T. Garlic and onion oils inhibit proliferation and induce differentiation of HL-60 cells. Cancer Lett 2000;160:29-35.
72. Dehghani F, Merat A, Panjehshahin MR, Handjani F. Healing effect of garlic extract on warts and corns. Int J Dermatol 2005;44:612-615.
73. Litt JZ. Don't excise-exorcise. Treatment for subungual and periungual warts. Cutis 1978;22:673-676.
74. Focht DR 3rd, Spicer C, Fairchok MP. The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart). Arch Pediatr Adolesc Med 2002;156:971-974.
75. Boyd AS, Neldner KH. The isomorphic response of Koebner. Int J Dermatol 1990;29:401-410.
76. Buckley D. Cryosurgery treatment of plantar warts. Ir Med J 2000;93:140-143.
77. Soroko YT, Repking MC, Clemment JA, Mitchell PL, Berg L. Treatment of plantar verrucae using 2% sodium salicylate iontophoresis. Phys Ther 2002;82:1184-1191.
78. Weiss G, Shemer A, Trau H. The Koebner phenomenon: review of the literature. J Eur Acad Dermatol Venereol 2002;16:241-248.
79. Vickers CF. Treatment of plantar warts in children. Br Med J 1961;5254:743-745.
80. Pringle WM, Helms DC. Treatment of plantar warts by blunt dissection. Arch Dermatol 1973;108:79-82.
81. Baruch K. Blunt dissection for the treatment of plantar verrucae. Cutis 1990;46:145-147, 151-152.
82. Matsumoto Y, Adachi A, Banno S, Hayashi Y, Ogiyama Y, Ohashi M. Prominent hyperkeratotic plantar and palmar warts. Cutis 1999;63:91-94.
83. Arndt KA, Bowers KE, Alam M, Reynolds R, Tsao S, eds. Warts. In: Manual of Dermatologic Therapeutics. 6th ed. Philadelphia: Lippincott, Williams & Wilkins; 2002:241-251.
84. Dunn PM. Dr Carl Crede (1819-1892) and the prevention of ophthalmia neonatorum. Arch Dis Child Fetal Neonatal Ed 2000;83:F158-F159.
85. Hanif J, Tasca RA, Frosh A, Ghufoor K, Stirling R. Silver nitrate: histological effects of cautery on epithelial surfaces with varying contact times. Clin Otolaryngol Allied Sci 2003;28:368-370.
86. Quitkin HM, Rosenwasser MP, Strauch RJ. The efficacy of silver nitrate cauterization for pyogenic granuloma of the hand. J Hand Surg [Am] 2003;28:435-438.
87. Daniels J, Craig F, Wajed R, Meates M. Umbilical granulomas: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 2003;88:F257.
88. Burton MJ, Doree CJ. Interventions for recurrent idiopathic epistaxis (nosebleeds) in children. Cochrane Database Syst Rev 2004;(1):CD004461.
89. Webb CJ, Beer H. Posterior nasal cautery with silver nitrate. J Laryngol Otol 2004;118:713-714.
90. Bray Healthcare. Silver nitrate pencil instructions. Bray Group Ltd, Faringdon, Oxon, UK. Available at: http://www.bray.co.uk/silver-nitrate-pencil. html. Accessed December 15, 2005.
91. Food and Drug Administration. Over-the-counter drug products containing colloidal silver ingredients or silver salts. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Final rule. Fed Regist 1999;64:44653-44658.
92. Yazar S, Basaran E. Efficacy of silver nitrate pencils in the treatment of common warts. J Dermatol 1994;21:329-333.
93. Baumbach JL, Sheth PB. Topical and intralesional antiviral agents. In: Wolverton S, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia, PA: W. B. Saunders Company; 2001:524-536.
94. Bedinghaus JM, Niedfeldt MW. Over-the-counter foot remedies. Am Fam Physician 2001;64:791-796.
95. Ahmed I, Agarwal S, Ilchyshyn A, Charles-Holmes S, Berth-Jones J. Liquid nitrogen cryotherapy of common warts: cryo-spray vs. cotton wool bud. Br J Dermatol 2001;144:1006-1009.
96. Gordon AH, Weinstein MV. Sodium salicylate iontophoresis in the treatment of plantar warts. Phys Ther 1969;49:869-870.
97. Bunney MH, Nolan MW, Williams DA. An assessment of methods of treating viral warts by comparative treatment trials based on a standard design. Br J Dermatol 1976;94:667-679.
98. Tabrizi SN, Garland SM. Is cryotherapy treating or infecting? Med J Aust 1996;164:263.
99. Connolly M, Bazmi K, O'Connell M, Lyons JF, Bourke JF. Cryotherapy of viral warts: a sustained 10-s freeze is more effective than the traditional method. Br J Dermatol 2001;145:554-557.
100. Berth-Jones J, Bourke J, Eglitis H, Harper C, Kirk P, Pavord S, Rajapakse R, Weston P, Wiggins T, Hutchinson PE. Value of a second freeze-thaw cycle in cryotherapy of common warts. Br J Dermatol 1994;131:883-886.
101. Bourke JF, Berth-Jones J, Hutchinson PE. Cryotherapy of common viral warts at intervals of 1, 2 and 3 weeks. Br J Dermatol 1995;132:433-436.
102. Bigby M, Gibbs S, Harvey I, Sterling J. Warts. Clin Evid 2004;(11):2209-2223.
103. Kang S, Fitzpatrick TB. Debilitating verruca vulgaris in a patient infected with the human immunodeficiency virus. Dramatic improvement with hyperthermia therapy. Arch Dermatol 1994;130:294-296.
104. LoCricchio J Jr, Haserick JR. Hot-water treatment for warts. Cleve Clin Q 1962;29:156-161.
105. Dvoretzky I. Hyperthermia therapy for warts utilizing a self-administered exothermic patch. Review of two cases. Dermatol Surg 1996;22:1035-1038.
106. Kent H. Plantar wart treatment with ultrasound. Arch Phys Med Rehabil 1959;40:15-18.
107. Rowe RJ, Gray JM. Ultrasound therapy of plantar warts. Arch Dermatol 1960;82:1008-1009.
108. Cherup N, Urben J, Bender LF. The treatment of plantar warts with ultrasound. Arch Phys Med Rehabil 1963;44:602-604.
109. Cohen HJ. Warts and ultrasound therapy. Arch Dermatol 1969;100:489.
110. Griffin JE, Gersten JW. What is the best method in the use of ultrasound for the treatment of plantar warts? Phys Ther 1971;51:82-83.
111. Vaughn DT. Direct method versus underwater method in the treatment of plantar warts with ultrasound. A comparative study. Phys Ther 1973;53:396-397.
112. Braatz JH, McAlistar BR, Broaddus MD. Ultrasound and plantar warts: a double blind study. Mil Med 1974;139:199-201.
113. Zaza M, Grassi C, Mardjonovic A, Valli E, Farne C, Romanini C. The use of electrosurgery in the treatment of extra-cervical genital condylomatosis. Minerva Ginecol 1998;50:367-371.
114. Tosti A, Piraccini BM. Warts of the nail unit: surgical and nonsurgical approaches. Dermatol Surg 2001;27:235-239.
115. Li HX, Zhu WY, Xia MY. Detection with the polymerase chain reaction of human papillomavirus DNA in condylomata acuminata treated with CO2 laser and microwave. Int J Dermatol 1995;34:209-211.
116. Bekassy Z, Westrom L. Infrared coagulation in the treatment of condyloma acuminata in the female genital tract. Sex Transm Dis 1987;14:209-212.
117. Piskin S, Aksoz T, Gorgulu A. The treatment of common warts with infrared coagulation. J Dermatol 2004;31:989-992.
118. Serour F, Somekh E. Successful treatment of recalcitrant warts in pediatric patients with carbon dioxide laser. Eur J Pediatr Surg 2003;13:219-223.
119. Lauchli S, Kempf W, Dragieva G, Burg G, Hafner J. CO2 laser treatment of warts in immunosuppressed patients. Dermatology 2003;206:148-152.
120. Ozluer SM, Chuen BY, Barlow RJ, Markey AC. Hypertrophic scar formation following carbon dioxide laser ablation of plantar warts in cyclosporin-treated patients. Br J Dermatol 2001;145:1005-1007.
121. Garden JM, O'Banion MK, Shelnitz LS, Pinski KS, Bakus AD, Reichmann ME, Sundberg JP. Papillomavirus in the vapor of carbon dioxide laser-treated verrucae. JAMA 1988;259:1199-1202.
122. Garden JM, O'Banion MK, Bakus AD, Olson C. Viral disease transmitted by laser-generated plume (aerosol). Arch Dermatol 2002;138:1303-1307.
123. Sawchuk WS, Weber PJ, Lowy DR, Dzubow LM. Infectious papillomavirus in the vapor of warts treated with carbon dioxide laser or electrocoagulation: detection and protection. J Am Acad Dermatol 1989;21:41-49.
124. Kashima HK, Kessis T, Mounts P, Shah K. Polymerase chain reaction identification of human papillomavirus DNA in CO2 laser plume from recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 1991;104:191-195.
125. Gloster HM Jr, Roenigk RK. Risk of acquiring human papillomavirus from the plume produced by the carbon dioxide laser in the treatment of warts. J Am Acad Dermatol 1995;32:436-441.
126. Tanzi EL, Bader RS. Cutaneous laser resurfacing: Erbium:YAG. eMedicine Web site. Available at: http://www.emedicine.com/derm/topic554.htm. Accessed December 28, 2005.
127. Park JH, Hwang ES, Kim SN, Kye YC. Er:YAG laser treatment of verrucous epidermal nevi. Dermatol Surg 2004;30:378-381.
128. Wollina U. Er:YAG laser followed by topical podophyllotoxin for hard-to-treat palmoplantar warts. J Cosmet Laser Ther 2003;5:35-37.
129. Hughes PS, Hughes AP. Absence of human papillomavirus DNA in the plume of erbium:YAG laser-treated warts. J Am Acad Dermatol 1998;38:426-428.
130. Pfau A, Abd-el-Raheem TA, Baumler W, Hohenleutner U, Landthaler M. Nd:YAG laser hyperthermia in the treatment of recalcitrant verrucae vulgares (Regensburg's technique). Acta Derm Venereol 1994;74:212-214.
131. Pfau A, Abd-El-Raheem TA, Baumler W, Hohenleutner U, Landthaler M. Treatment of recalcitrant verrucae vulgares with Nd:YAG laser hyperthermia (Regensburg's technique): preliminary results in 31 cases. J Dermatol Treat 1995;6:39-42.
132. El-Tonsy MH, Anbar TE, El-Domyati M, Barakat M. Density of viral particles in pre and post Nd:YAG laser hyperthermia therapy and cryotherapy in plantar warts. Int J Dermatol 1999;38:393-398.
133. Janda P, Leunig A, Sroka R, Betz CS, Rasp G. Preliminary report of endolaryngeal and endotracheal laser surgery of juvenile-onset recurrent respiratory papillomatosis by Nd:YAG laser and a new fiber guidance instrument. Otolaryngol Head Neck Surg 2004;131:44-49.
134. Buzalov S, Khristakieva E. Condylomata acuminata. The correlation between affecting sexual partners and the risk of developing preneoplasia of the cervix uteri. The therapeutic potentials of the Nd-Yag laser. Akush Ginekol (Sofiia). 1999;38(3):36-38.
135. Izumi T, Kyushima N, Genda T, Kobayashi N, Kanai T, Wakita K, Kuramoto H. Margin clearance and HPV infection do not influence the cure rates of early neoplasia of the uterine cervix by laser conization. Eur J Gynaecol Oncol 2000;21:251-254.
136. Wu C, Langan S, Kilmurray M, Lawlor D, Watson R. Efficacy of pulsed-dye laser for viral warts-an internal audit. Ir Med J 2003;96:80, 82-83.
137. Kopera D. Verrucae vulgares: flashlamp-pumped pulsed dye laser treatment in 134 patients. Int J Dermatol 2003;42:905-908.
138. Tuncel A, Gorgu M, Ayhan M, Deren O, Erdogan B. Treatment of anogenital warts by pulsed dye laser. Dermatol Surg 2002;28:350-352.
139. Vargas H, Hove CR, Dupree ML, Williams EF. The treatment of facial verrucae with the pulsed dye laser. Laryngoscope 2002;112:1573-1576.
140. Tan OT, Hurwitz RM, Stafford TJ. Pulsed dye laser treatment of recalcitrant verrucae: a preliminary report. Lasers Surg Med 1993;13:127-137.
141. Kauvar AN, McDaniel DH, Geronemus RG. Pulsed dye laser treatment of warts. Arch Fam Med 1995;4:1035-1040.
142. Huilgol SC, Barlow RJ, Markey AC. Failure of pulsed dye laser therapy for resistant verrucae. Clin Exp Dermatol 1996;21:93-95.
143. Jain A, Storwick GS. Effectiveness of the 585nm flashlamp-pulsed tunable dye laser (PTDL) for treatment of plantar verrucae. Lasers Surg Med 1997;21:500-505.
144. Jacobsen E, McGraw R, McCagh S. Pulsed dye laser efficacy as initial therapy for warts and against recalcitrant verrucae. Cutis 1997;59:206-208.
145. Kenton-Smith J, Tan ST. Pulsed dye laser therapy for viral warts. Br J Plast Surg 1999;52:554-558.
146. Ross BS, Levine VJ, Nehal K, Tse Y, Ashinoff R. Pulsed dye laser treatment of warts: an update. Dermatol Surg 1999;25:377-380.
147. Robson KJ, Cunningham NM, Kruzan KL, Patel DS, Kreiter CD, O'Donnell MJ, Arpey CJ. Pulsed-dye laser versus conventional therapy in the treatment of warts: a prospective randomized trial. J Am Acad Dermatol 2000;43:275-280.
148. Gooptu C, James MP. Recalcitrant viral warts: results of treatment with the KTP laser. Clin Exp Dermatol 1999;24:60-63.
149. Garcia-Zuazaga J, Cooper KD, Baron ED. Photodynamic therapy in dermatology: current concepts in the treatment of skin cancer. Expert Rev Anticancer Ther 2005;5:791-800.
150. Casas A, Batlle A. Rational design of 5-aminolevulinic acid derivatives aimed at improving photodynamic therapy. Curr Med Chem Anticancer Agents 2002;2:465-475.
151. Uebelhoer NS, Dover JS. Photodynamic therapy for cosmetic applications. Dermatol Ther 2005;18:242-252.
152. Fehr MK, Chapman CF, Krasieva T, Tromberg BJ, McCullough JL, Berns MW, Tadir Y. Selective photosensitizer distribution in vulvar condyloma acuminatum after topical application of 5-aminolevulinic acid. Am J Obstet Gynecol 1996;174:951-957.
153. Fehr MK, Hornung R, Degen A, Schwarz VA, Fink D, Haller U, Wyss P. Photodynamic therapy of vulvar and vaginal condyloma and intraepithelial neoplasia using topically applied 5-aminolevulinic acid. Lasers Surg Med 2002;30:273-279.
154. Stefanaki IM, Georgiou S, Themelis GC, Vazgiouraki EM, Tosca AD. In vivo fluorescence kinetics and photodynamic therapy in condylomata acuminata. Br J Dermatol 2003;149:972-976.
155. Wang XL, Wang HW, Wang HS, Xu SZ, Liao KH, Hillemanns P. Topical 5-aminolaevulinic acid-photodynamic therapy for the treatment of urethral condylomata acuminata. Br J Dermatol 2004;151:880-885.
156. Ross EV, Romero R, Kollias N, Crum C, Anderson RR. Selectivity of protoporphyrin IX fluorescence for condylomata after topical application of 5-aminolaevulinic acid: implications for photodynamic treatment. Br J Dermatol 1997;137:736-742.
157. Stender IM, Lock-Andersen J, Wulf HC. Recalcitrant hand and foot warts successfully treated with photodynamic therapy with topical 5-aminolaevulinic acid: a pilot study. Clin Exp Dermatol 1999;24:154-159.
158. Stender IM, Na R, Fogh H, Gluud C, Wulf HC. Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial. Lancet 2000;355:963-966.
159. Mizuki D, Kaneko T, Hanada K. Successful treatment of topical photodynamic therapy using 5-aminolevulinic acid for plane warts. Br J Dermatol 2003;149:1087-1088.
160. Schroeter CA, Pleunis J, van Nispen tot Pannerden C, Reineke T, Neumann HA. Photodynamic therapy: new treatment for therapy-resistant plantar warts. Dermatol Surg 2005;31:71-75.
161. Fabbrocini G, Di Costanzo MP, Riccardo AM, Quarto M, Colasanti A, Roberti G, Monfrecola G. Photodynamic therapy with topical delta-aminolaevulinic acid for the treatment of plantar warts. J Photochem Photobiol B 2001;61:30-34.
162. Bhat RM, Vidya K, Kamath G. Topical formic acid puncture technique for the treatment of common warts. Int J Dermatol 2001;40:415-419.
163. Andrei G, Snoeck R, Piette J, Delvenne P, De Clercq E. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol Res 1998;10:523-531.
164. De Clercq E, Andrei G, Balzarini J, Hatse S, Liekens S, Naesens L, Neyts J, Snoeck R. Antitumor potential of acyclic nucleoside phosphonates. Nucleosides Nucleotides 1999;18:759-771.
165. De Clercq E, Andrei G, Balzarini J, Leyssen P, Naesens L, Neyts J, Pannecouque C, Snoeck R, Ying C, Hockova D, Holy A. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2 (phosphonomethoxy) alkoxy]-2, 4-diaminopyrimidines. Nucleosides Nucleotides Nucleic Acids 2005;24:331-341.
166. Hengge UR, Tietze G. Successful treatment of recalcitrant condyloma with topical cidofovir. Sex Transm Infect 2000;76:143.
167. Schurmann D, Bergmann F, Temmesfeld-Wollbruck B, Grobusch MP, Suttorp N. Topical cidofovir is effective in treating extensive penile condylomata acuminata. AIDS 2000;14:1075-1076.
168. Snoeck R, Noel JC, Muller C, De Clercq E, Bossens M. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J Med Virol 2000;60:205-209.
169. Orlando G, Fasolo MM, Beretta R, Signori R, Adriani B, Zanchetta N, Cargnel A. Intralesional or topical cidofovir (HPMPC, VISTIDE) for the treatment of recurrent genital warts in HIV-1-infected patients. AIDS 1999;13:1978-1980.
170. Matteelli A, Beltrame A, Graifemberghi S, Forleo MA, Gulletta M, Ciravolo G, Tedoldi S, Casalini C, Carosi G. Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons. Sex Transm Dis 2001;28:343-346.
171. Turnbull JR, Husak R, Treudler R, Zouboulis CC, Orfanos CE. Regression of multiple viral warts in a human immunodeficiency virus-infected patient treated by triple antiretroviral therapy. Br J Dermatol 2002;146:330.
172. van der Velden EM, Ijsselmuiden OE, Drost BH, Baruchin AM. Dermatography with bleomycin as a new treatment for verrucae vulgaris. Int J Dermatol 1997;36:145-150.
173. Sobh MA, Abd El-Razic MM, Rizc RA, Eid MM, Abd el-Hamid IA, Ghoneim MA. Intralesional injection of bleomycin sulphate into resistant warts in renal transplant recipients versus non-transplant warty patients. Acta Derm Venereol 1991;71:63-66.
174. James MP, Collier PM, Aherne W, Hardcastle A, Lovegrove S. Histologic, pharmacologic, and immunocytochemical effects of injection of bleomycin into viral warts. J Am Acad Dermatol 1993;28:933-937.
175. Epstein E. Intralesional bleomycin and Raynaud's phenomenon. J Am Acad Dermatol 1991;24:785-786.
176. Vanhooteghem O, Richert B, de la Brassinne M. Raynaud phenomenon after treatment of verruca vulgaris of the sole with intralesional injection of bleomycin. Pediatr Dermatol 2001;18:249-251.
177. Abess A, Keel DM, Graham BS. Flagellate hyperpigmentation following intralesional bleomycin treatment of verruca plantaris. Arch Dermatol 2003;139:337-339.
178. Shumer SM, O'Keefe EJ. Bleomycin in the treatment of recalcitrant warts. J Am Acad Dermatol 1983;9:91-96.
179. Sollitto RJ, Pizzano DM. Bleomycin sulfate in the treatment of mosaic plantar verrucae: a follow-up study. J Foot Ankle Surg 1996;35:169-172.
180. Shelley WB, Shelley ED. Intralesional bleomycin sulfate therapy for warts. A novel bifurcated needle puncture technique. Arch Dermatol 1991;127:234-236.
181. Werfel S, Wolff H. Bleomycin prick in therapy-resistant verruca vulgaris. Hautarzt. 2001;52:638-641.
182. Munn SE, Higgins E, Marshall M, Clement M. A new method of intralesional bleomycin therapy in the treatment of recalcitrant warts. Br J Dermatol 1996;135:969-971.
183. Jason J, Archibald LK, Nwanyanwu OC, Sowell AL, Buchanan I, Larned J, Bell M, Kazembe PN, Dobbie H, Jarvis WR. Vitamin A levels and immunity in humans. Clin Diagn Lab Immunol 2002;9:616-621.
184. Bartsch D, Boye B, Baust C, zur Hausen H, Schwarz E. Retinoic acid-mediated repression of human papillomavirus 18 transcription and different ligand regulation of the retinoic acid receptor beta gene in non-tumorigenic and tumorigenic HeLa hybrid cells. EMBO J 1992;11:2283-2291.
185. Faluhelyi Z, Rodler I, Csejtey A, Tyring SK, Ember IA, Arany I. All-trans retinoic acid (ATRA) suppresses transcription of human papillomavirus type 16 (HPV16) in a dose-dependent manner. Anticancer Res 2004;24:807-809.
186. Kubeyinje EP. Evaluation of the efficacy and safety of 0.05% tretinoin cream in the treatment of plane warts in Arab children. J Dermatol Treat 1996;7:21-22.
187. Gelmetti C, Cerri D, Schiuma AA, Menni S. Treatment of extensive warts with etretinate: a clinical trial in 20 children. Pediatr Dermatol 1987;4:254-258.
188. Boyle J, Dick DC, MacKie RM. Treatment of extensive virus warts with etretinate (Tigason) in a patient with sarcoidosis. Clin Exp Dermatol 1983;8:33-36.
189. Gross G, Pfister H, Hagedorn M, Stahn R. Effect of oral aromatic retinoid (Ro 10-9359) on human papilloma virus-2-induced common warts. Dermatologica 1983;166:48-53.
190. Tsambaos D, Georgiou S, Monastirli A, Sakkis T, Sagriotis A, Goerz G. Treatment of condylomata acuminata with oral isotretinoin. J Urol 1997;158:1810-1812.
191. Georgala S, Katoulis AC, Georgala C, Bozi E, Mortakis A. Oral isotretinoin in the treatment of recalcitrant condylomata acuminata of the cervix: a randomised placebo controlled trial. Sex Transm Infect 2004;80:216-218.
192. Abu J, Batuwangala M, Herbert K, Symonds P. Retinoic acid and retinoid receptors: potential chemopreventive and therapeutic role in cervical cancer. Lancet Oncol 2005;6:712-720.
193. Schwartz J, Norton SA. Useful plants of dermatology. VI. The mayapple (Podophyllum). J Am Acad Dermatol 2002;47:774-775.
194. Fondren BT. Mayapple. Ethnobotanical leaflets, a publication of the Southern Illinois University Herbariaum. Available at: http://www.siu.edu/~ebl/ leaflets/mayapple.htm. Accessed December 7, 2005.
195. Kaplan IW. Condylomata acuminate. N Orleans Med Surg J 1942;93:388.
196. Nelson LM. Use of podophyllin (podophyllum resin) in dermatology. AMA Arch Derm Syphilol 1953;67:488-495
197. Stone KM, Becker TM, Hadgu A, Kraus SJ. Treatment of external genital warts: a randomised clinical trial comparing podophyllin, cryotherapy, and electrodesiccation. Genitourin Med 1990;66:16-19
198. The Condylomata International Collaborative Study Group. A comparison of interferon alfa-2a and podophyllin in the treatment of primary condylomata acuminata. Genitourin Med 1991;67:394-399.
199. Goh CL, Ang CB, Chan RK, Cheong WK. Comparing treatment response and complications between podophyllin 0.5%/0.25% in ethanol vs podophyllin 25% in tincture benzoin for penile warts. Singapore Med J 1998;39:17-19.
200. Gabriel G, Thin RN. Treatment of anogenital warts. Comparison of trichloracetic acid and podophyllin versus podophyllin alone. Br J Vener Dis 1983;59:124-126.
201. von Krogh G, Wikstrom A. Efficacy of chemical and/or surgical therapy against condylomata acuminata: a retrospective evaluation. Int J STD AIDS 1991;2:333-338.
202. Mohanty KC. The cost effectiveness of treatment of genital warts with podophyllotoxin. Int J STD AIDS 1994;6:253-256.
203. von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001;11:598-603.
204. von Krogh G, Longstaff E. Podophyllin office therapy against condyloma should be abandoned. Sex Transm Infect 2001;77:409-412.
205. Lacey CJ, Goodall RL, Tennvall GR, Maw R, Kinghorn GR, Fisk PG, Barton S, Byren I; Perstop Pharma Genital Warts Clinical Trial Group. Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. Sex Transm Infect 2003;79:270-275.
206. Filley CM, Graff-Richard NR, Lacy JR, Heitner MA, Earnest MP. Neurologic manifestations of podophyllin toxicity. Neurology 1982;32:308-311.
207. Chattopadhyay S, Srivastava AK, Bhojwani SS, Bisaria VS. Production of podophyllotoxin by plant cell cultures of Podophyllum hexandrum in bioreactor. J Biosci Bioeng 2002;93:215-220.
208. Seif R. Factors which disorganize microtubules or microfilaments increase the frequency of cell transformation by polyoma virus. J Virol 1980;36:421-428.
209. Kirby P, Dunne A, King DH, Corey L. Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts. Am J Med 1990;88:465-469.
210. Hellberg D, Svarrer T, Nilsson S, Valentin J. Self-treatment of female external genital warts with 0.5% podophyllotoxin cream (Condyline) vs weekly applications of 20% podophyllin solution. Int J STD AIDS 1995;6:257-261.
211. Ibs KH, Rink L. Zinc-altered immune function. J Nutr 2003;133:1452S- 1526S.
212. Fraker PJ, King LE. Reprogramming of the immune system during zinc deficiency. Annu Rev Nutr 2004;24:277-298.
213. Al-Gurairi FT, Al-Waiz M, Sharquie KE. Oral zinc sulphate in the treatment of recalcitrant viral warts: randomized placebo-controlled clinical trial. Br J Dermatol 2002;146:423-431.
214. Upitis JA, Krol A. The use of diphenylcyclopropenone in the treatment of recalcitrant warts. J Cutan Med Surg 2002;6:214-217.
215. Higgins E, du Vivier A. Topical immunotherapy: unapproved uses, dosages, or indications. Clin Dermatol 2002;20:515-521.
216. Buckley DA, Keane FM, Munn SE, Fuller LC, Higgins EM, Du Vivier AW. Recalcitrant viral warts treated by diphencyprone immunotherapy. Br J Dermatol 1999;141:292-296.
217. Friedman-Kien AE, Eron LJ, Conant M, Growdon W, Badiak H, Bradstreet PW, Fedorczyk D, Trout JR, Plasse TF. Natural interferon alfa for treatment of condylomata acuminata. JAMA 1988;259:533-538.
218. Lozada-Nur F, Glick M, Schubert M, Silverberg I. Use of intralesional interferon-alpha for the treatment of recalcitrant oral warts in patients with AIDS: a report of 4 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92:617-622.
219. Johnson SM, Roberson PK, Horn TD. Intralesional injection of mumps or Candida skin test antigens: a novel immunotherapy for warts. Arch Dermatol 2001;137:451-455.
220. Signore RJ. Candida albicans intralesional injection immunotherapy of warts. Cutis 2002;70:185-192.
221. Perman M, Sterling JB, Gaspari A. The painful purple digit: an alarming complication of Candida albicans antigen treatment of recalcitrant warts. Dermatitis 2005;16:38-40.
222. Iscimen A, Aydemir EH, Goksugur N, Engin B. Intralesional 5-fluorouracil, lidocaine and epinephrine mixture for the treatment of verrucae: a prospective placebo-controlled, single-blind randomized study. J Eur Acad Dermatol Venereol 2004;18:455-458.
223. Rogers CJ, Gibney MD, Siegfried EC, Harrison BR, Glaser DA. Cimetidine therapy for recalcitrant warts in adults: is it any better than placebo? J Am Acad Dermatol 1999;41:123-127.
224. Mitsuishi T, Iida K, Kawana S. Cimetidine treatment for viral warts enhances IL-2 and IFN-gamma expression but not IL-18 expression in lesional skin. Eur J Dermatol 2003;13:445-448.
225. Karabulut AA, Sahin S, Eksioglu M. Is cimetidine effective for nongenital warts: a double-blind, placebo-controlled study. Arch Dermatol 1997;133:533-534.
226. Yilmaz E, Alpsoy E, Basaran E. Cimetidine therapy for warts: a placebo-controlled, double-blind study. J Am Acad Dermatol 1996;34:1005-1007.
227. Mullen BR, Guiliana JV, Nesheiwat F. Cimetidine as a first-line therapy for pedal verruca: eight-year retrospective analysis. J Am Podiatr Med Assoc 2005;95:229-234.
228. Amer M, Tosson Z, Soliman A, Selim AG, Salem A, al-Gendy AA. Verrucae treated by levamisole. Int J Dermatol 1991;30:738-740.
229. Hengge UR, Esser S, Schultewolter T, Behrendt C, Meyer T, Stockfleth E, Goes M. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol 2000;143:1026-1031.
230. Micali G, Dall'Oglio F, Nasca MR. An open label evaluation of the efficacy of imiquimod 5% cream in the treatment of recalcitrant subungual and periungual cutaneous warts. J Dermatolog Treat 2003;14:233-236.
231. Poochareon V, Berman B, Villa A. Successful treatment of butcher's warts with imiquimod 5% cream. Clin Exp Dermatol 2003;28(Suppl 1):42-44.
232. Sauder DN, Skinner RB, Fox TL, Owens ML. Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations. Sex Transm Dis 2003;30:124-128.
233. Zamiri M, Gupta G. Plantar warts treated with an immune response modifier: a report of two cases. Clin Exp Dermatol 2003;28(Suppl 1):45-47.
234. Hesterberg U, Bohlen LM, Brand CU. Imiquimod in the treatment of recalcitrant warts: a new therapy option? Schweiz Rundsch Med Prax. 2003;92:535-539.
235. Arican O, Guneri F, Bilgic K, Karaoglu A. Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study. J Dermatol 2004;31:627-631.
236. Hoyme UB, Hagedorn M, Schindler AE, Schneede P, Hopfenmuller W, Schorn K, Eul A. Effect of adjuvant imiquimod 5% cream on sustained clearance of anogenital warts following laser treatment. Infect Dis Obstet Gynecol 2002;10:79-88.
237. Skinner RB Jr. Imiquimod. Dermatol Clin 2003;21:291-300.
238. Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999;353:1689-1694.
239. Bohle A, Thanhauser A, Ulmer AJ, Ernst M, Flad HD, Jocham D. Dissecting the immunobiological effects of Bacillus Calmette-Guerin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J Urol 1993;150:1932-1937.
240. Bohle A, Thanhauser A, Ulmer AJ, Mattern T, Ernst M, Flad HD, Jocham D. On the mode of action of intravesical bacillus Calmette-Guerin: in vitro characterization of BCG-activated killer cells. Urol Res 1994;22:185-190.
241. Guidotti LG, Chisari FV. To kill or to cure: options in host defense against viral infection. Curr Opin Immunol 1996;8:478-483.
242. Kershaw MH, Trapani JA, Smyth MJ. Cytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer. Ther Immunol 1995;2:173-181.
243. Bohle A, Doehn C, Kausch I, Jocham D. Treatment of recurrent penile condylomata acuminata with external application and intraurethral instillation of bacillus Calmette-Guerin. J Urol 1998;160:394-396.
244. Bohle A, Buttner H, Jocham D. Primary treatment of condylomata acuminata with viable bacillus Calmette-Guerin. J Urol 2001;165:834-836.
245. Metawea B, El-Nashar AR, Kamel I, Kassem W, Shamloul R. Application of viable bacille Calmette-Guerin topically as a potential therapeutic modality in condylomata acuminata: a placebo-controlled study. Urology 2005;65:247-250.
246. Abcarian H, Sharon N. Long-term effectiveness of the immunotherapy of anal condyloma acuminatum. Dis Colon Rectum 1982;25:648-651.
247. Harper DM. Are we closer to the prevention of HPV-related diseases? J Fam Pract 2005;54(7 Suppl):S10-S16.
248. Hussain SF, Paterson Y. What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors. Cancer Immunol Immunother 2005;54:577-586.
249. Kahn JA, Bernstein DI. Human papillomavirus vaccines and adolescents. Curr Opin Obstet Gynecol 2005;17:476-482.
250. Kahn JA, Zimet GD, Bernstein DI, Riedesel JM, Lan D, Huang B, Rosenthal SL. Pediatricians' intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health 2005;37:502-510.
251. Williamson AL, Passmore JA, Rybicki EP. Strategies for the prevention of cervical cancer by human papillomavirus vaccination. Best Pract Res Clin Obstet Gynaecol 2005;19:531-544.
252. Yang R, Wheeler CM, Chen X, Uematsu S, Takeda K, Akira S, Pastrana DV, Viscidi RP, Roden RB. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer. J Virol 2005;79:6741-6750.
253. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991;185:251-257
254. Poland GA, Jacobson RM, Koutsky LA, Tamms GM, Railkar R, Smith JF, Bryan JT, Cavanaugh PF Jr, Jansen KU, Barr E. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial. Mayo Clin Proc 2005;80:601-610.
255. Brown DR, Bryan JT, Schroeder JM, Robinson TS, Fife KH, Wheeler CM, Barr E, Smith PR, Chiacchierini L, DiCello A, Jansen KU. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. J Infect Dis 2001;184:1183-1186.
256. Emeny RT, Wheeler CM, Jansen KU, Hunt WC, Fu TM, Smith JF, MacMullen S, Esser MT, Paliard X. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol 2002;76:7832-7842.
257. Brown DR, Fife KH, Wheeler CM, Koutsky LA, Lupinacci LM, Railkar R, Suhr G, Barr E, Dicello A, Li W, Smith JF, Tadesse A, Jansen KU. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine 2004;22:2936-2942.
258. Fife KH, Wheeler CM, Koutsky LA, Barr E, Brown DR, Schiff MA, Kiviat NB, Jansen KU, Barber H, Smith JF, Tadesse A, Giacoletti K, Smith PR, Suhr G, Johnson DA. Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. Vaccine 2004;22:2943-2952.
259. Ault KA, Giuliano AR, Edwards RP, Tamms G, Kim LL, Smith JF, Jansen KU, Allende M, Taddeo FJ, Skulsky D, Barr E. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 2004;22:3004-3007.
260. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU; Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-1651.
261. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G; GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-1765.
262. Lowndes CM, Gill ON. Cervical cancer, human papillomavirus, and vaccination. BMJ 2005;331:915-916.
263. Finn A. Details of HPV immunisation need not delay decision. BMJ 2005;331:1081.
264. Gill ON, Lowndes CM. Data are still needed for HPV immunisation programme. BMJ 2005;331:1204.
265. WHO. WHO consultation on human papillomavirus vaccines. Wkly Epidemiol Rec 2005;80:299-302.
266. Grunbaum JA, Kann L, Kinchen S, Ross J, Hawkins J, Lowry R, Harris WA, McManus T, Chyen D, Collins J. Youth risk behavior surveillance-United States, 2003. MMWR Surveill Summ 2004;53:1-96.
267. Soubeyrand B, Leparc J. Vaccination against human papillomavirus: a new vaccination for the female adolescent? Med Mal Infect 2005 Oct 24; [Epub ahead of print].
268. Washam C. Targeting teens and adolescents for HPV vaccine could draw fire. J Natl Cancer Inst 2005;97:1030-1031.
269. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003;290:781-789.
270. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004;103:619-631.
271. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, Wacholder S, Kendal H, Breheny AM, Prior A, Pfeiffer R, Burk RD. PCR testing of pooled longitudinally collected cervical specimens of women to increase the efficiency of studying human papillomavirus infection. Cancer Epidemiol Biomarkers Prev 2005;14:256-260.
272. Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright TC Jr. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA 2005;294:2173-2181.
273. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst 2005;97:888-895.
274. Mayneux EJ Jr. Overcoming barriers to HPV vaccine acceptance. J Fam Pract 2005;54:S17-S22.
275. Olshen E, Woods ER, Austin SB, Luskin M, Bauchner H. Parental acceptance of the human papillomavirus vaccine. J Adolesc Health 2005;37:248-251.
276. Gravitt PE, Shah KV. A Virus-based Vaccine May Prevent Cervical Cancer. Curr Infect Dis Rep 2005;7:125-131.
277. Bushley AW, Cassel K, Hernandez BY, Robinett H, Goodman MT. A tailored multi-media campaign to promote the human papillomavirus cohort study to young women. Prev Med 2005;41:98-101.
278. McClean H, Shann S. A cross-sectional survey of treatment choices for anogenital warts. Int J STD AIDS 2005;16:212-216.
279. Sparling JD, Checketts SR, Chapman MS. Imiquimod for plantar and periungual warts. Cutis 2001;68:397-399.
280. Tucker SB, Ali A, Ransdell BL. Plantar wart treatment with combination imiquimod and salicylic acid pads. J Drugs Dermatol 2003;2:124-126.
281. Housman TS, Jorizzo JL. Anecdotal reports of 3 cases illustrating a spectrum of resistant common warts treated with cryotherapy followed by topical imiquimod and salicylic acid. J Am Acad Dermatol 2002;47:S217-S220.
282. Young S, Cohen GE. Treatment of verruca plantaris with a combination of topical fluorouracil and salicylic acid. J Am Podiatr Med Assoc 2005;95:366-369.
283. Olsen EA, Kelly FF, Vollmer RT, Buddin DA, Week PK. Comparative study of systemic interferon alfa-n1 and isotretinoin in the treatment of resistant condylomata acuminata. J Am Acad Dermatol 1989;20:1023-1030.
284. Cardamakis E, Kotoulas IG, Relakis K, Metalinos K, Michopoulos J, Stathopoulos E, Mantouvalos H. Comparative study of systemic interferon alfa-2a plus isotretinoin versus isotretinoin in the treatment of recurrent condyloma acuminatum in men. Urology 1995;45:857-860.
285. Cardamakis EK, Kotoulas IG, Dimopoulos DP, Stathopoulos EN, Michopoulos JT, Tzingounis VA. Comparative study of systemic interferon alfa-2a with oral isotretinoin and oral isotretinoin alone in the treatment of recurrent condylomata accuminata. Arch Gynecol Obstet 1996;258:35-41.
286. Yildirim M, Inaloz HS, Baysal V, Kesici D, Candir O. A case of condyloma acuminatum treated successfully with low-dose isotretinoin and interferon. Int J Clin Pract 2004;58:889-891.
287. Anadolu R, Oskay T, Erdem C, Boyvat A, Terzi E, Gurgey E. Treatment of epidermodysplasia verruciformis with a combination of acitretin and interferon alfa-2a. J Am Acad Dermatol 2001;45:296-299.
288. Gubinelli E, Posteraro P, Cocuroccia B, Girolomoni G. Epidermodysplasia verruciformis with multiple mucosal carcinomas treated with pegylated interferon alfa and acitretin. J Dermatolog Treat 2003;14:184-188.
289. Douglas JM Jr, Eron LJ, Judson FN, Rogers M, Alder MB, Taylor E, Tanner D, Peets E. A randomized trial of combination therapy with intralesional interferon alpha 2b and podophyllin versus podophyllin alone for the therapy of anogenital warts. J Infect Dis 1990;162:52-59.
290. Kruse AJ, Baak JP, Janssen EA, Bol MG, Kjellevold KH, Fianne B, Lovslett K, Bergh J. Low- and high-risk CIN 1 and 2 lesions: prospective predictive value of grade, HPV, and Ki-67 immuno-quantitative variables. J Pathol 2003;199:462-470.
291. Okamoto A, Woodworm CD, Yen K, Chung J, Isonishi S, Nikaido T, Kiyokawa T, Seo H, Kitahara Y, Ochiai K, Tanaka T. Combination therapy with podophyllin and vidarabine for human papillomavirus positive cervical intraepithelial neoplasia. Oncol Rep 1999;6:269-276.
292. Pollock B, Sheehan-Dare R. Pulsed dye laser and intralesional bleomycin for treatment of resistant viol hand warts. Lasers Surg Med 2002;30:135-140.
293. Hua Z, Gibson SL, Foster TH, Hilf R. Effectiveness of delta-aminolevulinic acid-induced protoporphyrin as a photosensitizer for photodynamic therapy in vivo. Cancer Res 1995;55:1723-1731.
294. Smucler R, Jatsova E. Comparative study of aminolevulic acid photodynamic therapy plus pulsed dye laser versus pulsed dye laser alone in treatment of viral warts. Photomed Laser Surg 2005;23:202-205.
295. Johnson SM, Horn TD. Intralesional immunotherapy for warts using a combination of skin test antigens: a safe and effective therapy. J Drugs Dermatol 2004;3:263-265.
296. Parsad D, Saini R, Negi KS. Comparison of combination of cimetidine and levamisole with cimetidine alone in the treatment of recalcitrant warts. Australas J Dermatol 1999;40:93-95.
297. Parsad D, Pandhi R, Juneja A, Negi KS. Cimetidine and levamisole versus cimetidine alone for recalcitrant warts in children. Pediatr Dermatol 2001;18:349-352.
298. Orlando G, Fasolo MM, Beretta R, Merli S, Cargnel A. Combined surgery and cidofovir is an effective treatment for genital warts in HIV-infected patients. AIDS 2002;16:447-450.
299. King E. What are NNRTIs?: An overview of how they work and their current availability. Aids Treatment Update 1996;43:e1-e2. Available at: http://www.aegis.com/pubs/atu/1996/atu4302.html. Accessed May 15, 2006.
300. Spach DH, Colven R. Resolution of recalcitrant hand warts in an HIV-infected patient treated with potent antiretroviral therapy. J Am Acad Dermatol 1999;40:818-821.
301. Roark TR, Pandya AG. Combination therapy of resistant warts in a patient with AIDS. Dermatol Surg 1998;24:1387-1389.